Glenmark names president, North america and global API business
This article was originally published in Scrip
Glenmark Pharmaceuticals, a global, integrated pharmaceutical company headquartered in Mumbai, India, has named Philip Andrew Gioia president of the firm's North American and Global API business. He will report to chair and managing director Glenn Saldanha. Mr Gioia joins the firm from Bausch & Lomb (acquired by Valeant Pharmaceuticals, August 2013), where he was global head of diversified products and business development, pharmaceuticals division.